Lisa Bodei, MD, PhD
Nuclear Medicine Physician & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Nuclear Medicine
- Molecular Imaging and Targeted Radionuclide Therapy
- PET
Request an Appointment
About Me
- Director of Targeted Radionuclide Therapy
I am a nuclear medicine physician who has extensive experience and broad expertise in therapeutic and diagnostic applications of nuclear medicine in oncology.
Read more
My past clinical and research experience has been multifaceted, and includes combining the therapeutic and diagnostic components of nuclear medicine, which is referred to as theranostics. From the therapeutic perspective, my special expertise is in the development of peptide receptor radionuclide therapy (PRRT) of gut and lung neuroendocrine tumors, including special investigational and molecular translational analyses to facilitate their diagnosis and therapy. In addition, I have substantial experience with radioiodine therapy of differentiated thyroid cancer and hyperthyroidism. I also have expertise in the utilization of systemic radioimmunotherapy for loco-regional disease, brain tumors, ovarian carcinoma, and non-Hodgkin lymphoma.
In the diagnostic arena my expertise includes a broad range of diagnostic endocrine applications in nuclear medicine such as receptor scintigraphy, 68Ga-octreotide PET/TC, 18FDG-PET/CT in oncology, radio-immuno-scintigraphy, and sentinel node scintigraphy.
I am the author or co-author of more than 100 peer-reviewed publications, and serve on the editorial boards of several scientific journals including the Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.
A nuclear medicine physician is a doctor with special training in using radioactive drugs to diagnose and treat disease.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Nuclear Medicine
- Molecular Imaging and Targeted Radionuclide Therapy
- PET
Education
- MD, University of Pisa (Italy)
- PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen (Netherlands)
Residencies
- School of Specialization in Nuclear Medicine, University of Pisa (Italy)
Awards and Honors
- Most Distinguished Italian Researcher Award, for clinical research activities on neuroendocrine tumors and multiple endocrine neoplasia, Italian Association of Neuroendocrine Tumors, NPO, (2012)
- "For Women by Women" Award, Italian Association for Neuroendocrine Tumors, NPO (2012)
- Award for the Scientific Contribution to the European Congress of Endocrinology (2013)
Fellowships
- Nuclear Medicine Division, European Institute of Oncology (Milan, Italy)
Board Certifications
- Nuclear Medicine (US)
- Nuclear Medicine (Italy)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Bodei sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Bodei
- A Phase I Study of 177Lu-DOTA-EB-TATE in People with Advanced Neuroendocrine Cancers
- Clinical Trials Co-Investigated by Dr. Bodei
- A Study Comparing Lutetium Edotreotide with Standard Treatments in People with Digestive Neuroendocrine Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Bodei’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lisa Bodei discloses the following relationships and financial interests:
-
American Board of Nuclear Medicine
Professional Services and Activities (Uncompensated) -
European Journal of Nuclear Medicine and Molecular Imaging
Professional Services and Activities (Uncompensated) -
European Society for Medical Oncology (ESMO)
Professional Services and Activities (Uncompensated) -
Journal of Nuclear Medicine
Professional Services and Activities (Uncompensated) -
National Cancer Institute
Professional Services and Activities (Uncompensated) -
Neuroendocrine Tumor Research Foundation
Professional Services and Activities (Uncompensated)
-
POINT Biopharma Global Inc.
Professional Services and Activities (Uncompensated) -
RayzeBio, Inc.
Professional Services and Activities (Uncompensated) -
Society of Nuclear Medicine and Molecular Imaging
Professional Services and Activities (Uncompensated) -
Solve Therapeutics, Inc.
Professional Services and Activities (Uncompensated) -
The Quarterly Journal of Nuclear Medicine and Molecular Imaging
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].